Alcidion Group (ALC) Q4 2026 earnings summary

Executive summary

• Achieved record positive operating cash flow of AUD 7.7 million in Q4 and AUD 6.8 million for the full year, up 19% year-over-year, surpassing FY 2026 guidance.

• Secured milestone contracts, including a $35 million, 7-year contract with University Hospitals Sussex for Miya Precision and a 4-year extension with Western Health.

• Completed the acquisition of Kyra flow product suite from Telstra Health, adding 33 customers and strengthening presence in Queensland.

• Cash balance at June 30, 2026, was AUD 20.6 million with no debt.

Financial highlights

• FY 2026 revenue guidance confirmed at AUD 51.6 million, a 27% increase year-over-year, with EBITDA expected to exceed AUD 5 million.

• Q4 new sales and renewals reached AUD 43.2 million, with 89% recurring product revenue.

• Full year new TCV sales hit AUD 78.5 million, a company record.

• Q4 cash receipts from customers totaled AUD 24.6 million, including a significant upfront payment from UHS.

• Product development and operating costs for Q4 were AUD 4.1 million, reflecting higher third-party provider payments.

Outlook and guidance

• High confidence in FY 2026 revenue of AUD 51.6 million and EBITDA above AUD 5 million, subject to audit.

• Strong momentum entering FY 2027, with a significant book of implementation revenue carrying over.

• Detailed FY27 contracted revenue update to be provided with full-year FY26 results in August.

• Continued focus on expanding in existing and new markets, including Southeast Asia.